ICMRA statement on continuation of vaccine trials

ICMRA urges all stakeholders, including vaccines researchers and investigators, academia, regulators and the pharmaceutical industry to continue COVID-19 vaccine trials beyond the time when the pre-defined cases of COVID-19 disease for final analysis in a trial have been reached. This can provide important additional and more precise information on longer-term safety and efficacy of a vaccine against COVID-19.

ICMRA statement on continuation of vaccine trials (27 November 2020)

 

Statement in other languages